8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS

Completed · Phase 2

Conditions studied: Irritable Bowel Syndrome

In brief

In this study, female patients with IBS-d will be treated for 8 weeks to assess the safety and effectiveness of DDP225 on GI transit and in reducing IBS symptoms.

Key facts

Study ID

NCT00230581

Run by

Dynogen Pharmaceuticals

People needed

88

Starts

2005-09-01

Expected to finish

2007-08-01

Last updated by the study team

2007-10-15

Who can join

Age: 18 and older, up to 65. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female patients from 18 to 65 years of age, inclusive.
• History of IBS-d for at least 6 months prior to the initial screening visit.
• Endoscopic/radiologic bowel evaluation to rule out cancer, obstruction, or other structural disease.
• The patient must have completed at least six days of assessments in the patient diary in the one week period prior to the second screening visit.
• Negative serum and urine pregnancy tests and post-partum for at least one year or not breast feeding at the initial screening visit and throughout the study. For patients able to bear children, an acceptable method of birth control must be used throughout the study. Patients unable to bear children must have documentation of such in the case report form (i.e., tubal ligation, hysterectomy, or post-menopausal [defined as a minimum of one year since the last menstrual period]).
• Able to provide voluntary, written informed consent with comprehension of all aspects of the protocol.

You may not qualify if…

• Serious underlying diseases, including psychiatric disorders or current history of conditions affecting bowel transit including biochemical or structural abnormalities, or GI surgery
• Clinically significant abnormal examination findings or laboratory tests
• Inability to stop taking certain medications, or a planned change in medication (including herbal remedies) which could interfere with study assessments
• Use of drugs and or ethanol which may interfere with compliance of study procedures or influence study outcome
• Presence of a medical condition which could interfere with the interpretation of study data
• Significant use of nicotine or caffeine

Where it is running

• Radiant Research — Scottsdale, Arizona, United States
• Radiant Research — St Louis, Missouri, United States
• Long Island Gastrointestinal Research — Great Neck, New York, United States
• Radiant Research — Mogadore, Ohio, United States
• Radiant Research — Greer, South Carolina, United States
• QE II Health Sciences Centre — Halifax, Nova Scotia, Canada
• McMaster University Medical Centre — Hamilton, Ontario, Canada
• St. Joseph's Healthcare — Hamilton, Ontario, Canada
• Hotel Dieu Hospital — Kingston, Ontario, Canada
• St. Joseph's Healthcare — London, Ontario, Canada
• Meadowlands Family Health Centre — Ottawa, Ontario, Canada
• London Road Diagnostic Clinic — Sarnia, Ontario, Canada
• Sarnia Institute of Clinical Research — Sarnia, Ontario, Canada
• Canadian Phase Onward Inc. — Toronto, Ontario, Canada
• Toronto Digestive Disease Associates, Inc. — Toronto, Ontario, Canada
• Hopital St-Sacrement — Québec, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.